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The process of accommodation allows for the eye to focus 
on nearby objects. The mechanism by which this occurs in 
vertebrates involves either a translation of the lens or a change 
in the lens curvature to increase the optical power of the eye 
[1]. Humans and birds are similar in that both species use the 
latter method to accommodate [1,2]. However, the changes in 
the human lens occur via the relaxation of zonules attached 
to the ciliary muscle [1,3], whereas the ciliary muscle in the 
avian eye directly articulates with the equator of the lens [2], 
resulting in a squeezing of the lens in the equatorial plane.
The lens maintains its integrity and transparency due to 
the organization of its cells, which are epithelial in origin 
[4-6]. Similar to other epithelial cells in the body, lens epithe-
lial cells contain cytoskeletal filaments, the smallest of which 
are known as microfilaments and are found throughout the 
lens [7]. Microfilaments are composed largely of filamentous 
f-actin and are responsible for an array of essential biologic
functions, including facilitating changes in cell shape, forti-
fying cell–cell and cell–extracellular matrix interactions, and
compartmentalizing plasma membranes [8,9].
In most cells, the f-actin function relies on its ability 
to interact with myosin II, a non-muscle and smooth 
muscle motor protein, to form actomyosin assemblies [10]. 
In smooth- and non-muscle systems, the contraction of 
actin and myosin is triggered by myosin light chain kinase 
(MLCK), an upregulator of ATPase activity and a catalyst 
for actin-myosin cross-linking [11-13]. The ATP is used by 
myosin heads to move along actin filaments and results in the 
contractile movement of myofilaments. In squirrels, rabbits, 
and humans, f-actin is arranged in polygonal arrays at the 
anterior faces of crystalline lenses and is associated with 
myosin within the epithelium [14]. Similarly, at the posterior 
surface of the avian crystalline lens, f-actin, non-muscle 
myosin, and N-cadherin are arranged in a hexagonal lattice 
resembling a “two-dimensional muscle” [15]. The actomyosin 
complex at the anterior epithelium has been speculated to 
facilitate accommodation by allowing the epithelial cells to 
change shape or by permitting the lens as a whole to change 
into a more spherical shape [16]. Furthermore, the proteins 
collectively at the basal membrane complex (BMC) of the 
posterior lens surface have been shown to mediate fiber cell 
migration across, and anchor fiber cells to, the lens capsule 
[15]. In addition, the presence of highly regular actomyosin 
lattices in the lens raises the possibility that these networks 
are involved in setting the passive biomechanical response 
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of the avian lens to external forces, such as those exerted 
by the ciliary muscle. Indeed, previous research using 
knockout mice has shown that in the murine lens, beaded fila-
ments, which are intermediate filaments unique to the lens, 
contribute significantly to lens stiffness [17]. Furthermore, 
the fact that the actomyosin network has the potential to be 
contractile raises two even more intriguing possibilities: that 
lens stiffness could be actively tuned by adjusting the amount 
of tension in the network and that the shape of the lens itself 
could be similarly adjusted [15,16,18-20]. The demonstration 
that the MLCK inhibitor, ML-7, has significant effects on 
the focal length, and therefore almost certainly the shape 
of avian lenses seems to support this idea [21]. The purpose 
of this study was to test the hypothesis that lenticular acto-
myosin networks affect the biomechanics and optics of the 
whole avian lens by pharmacologically disrupting them and 
measuring the effects on lens stiffness and optical clarity.
METHODS
Animals: White leghorn (Gallus gallus domesticus) hatch-
ling chicks were obtained from the Maple Leaf hatchery 
in New Hamburg, Ontario and were fed ad libitum. They 
were housed in stainless steel brooders with a heat source 
and kept on a 14 h:10 h light-dark cycle. Chicks were raised 
in accordance with the Guidelines of the Canadian Council 
on Animal Care and with the ARVO Statement for the Use 
of Animals in Ophthalmic and Vision Research. As the 
focus of this study was to test the fundamental question of 
whether disrupting cytoskeletal proteins could have an effect 
on lenticular biomechanics, chicks with robust amounts of 
accommodation (about a week old) were used instead of older 
birds, which will be considered for a future study once the 
functions of disruptors have been well established. Week-old 
chicks also show highly monotonic spherical aberrations 
(SAs) [22], thereby providing a model against which optical 
changes could be assessed.
Lens dissections: Chicks that were 6–8 days old were sacri-
ficed by decapitation and their eyes were enucleated. Eyes 
were placed in chilled oxygenated Tyrode’s solution (TS: 
134 mM NaCl, 3 mM KCl, 20.5 mM NaHCO3, 1 mM MgCl2, 
3 mM CaCl2) before removal of the posterior globe and 
vitreous humor. The exposed lens was then separated from 
the surrounding ciliary body and extracted from the anterior 
segment, taking care to minimize damage to the lens capsule.
Disruptors: Latrunculin A (LAT-A) is a drug that rapidly, 
reversibly, and specifically disrupts actin cytoskeleton by 
preventing polymerization [23,24]. As well, 1-phenyl-1,2,3,4-
tetrahydro-4-hydroxypyrrolo[2.3-b]-7-methylquinolin-4-one 
(blebbistatin) is a reversible inhibitor with a specificity 
and high affinity for several class II myosins and acts by 
reducing the actin affinity of the myosin heads [25]. Finally, 
1-(5-Iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diaz-
epine hydrochloride (ML-7) selectively disrupts MLCK 
activity by preventing myosin II light-chain phosphorylation 
[26].
Lens treatments: For each bird, one eye was treated for 15 
min with either 10 μM latrunculin (n = 18) in 0.01% (v/v) 
dimethyl sulfoxide (DMSO) in TS, 10 μM blebbistatin (n = 
16) in 0.01% (v/v) DMSO in TS, or 10 μM ML-7 (n = 14) in
0.01% (v/v) DMSO in TS. The lenses from the opposite eyes
were subjected to a vehicle (0.01% (v/v) DMSO in TS; 15
min). Assignment to the treatment group alternated between
left and right eyes. All lenses were briefly rinsed in TS before
biomechanical testing, western blot analysis, immunocyto-
chemical processing, or assessment of optical quality.
Lens compressions: The mechanical properties of the lenses 
were measured using a universal testing machine (Instron, 
Norwood, MA). Each lens was placed anterior side down on 
a pedestal located in the compression chamber containing 
chilled TS (Figure 1). Lenses were then compressed by 0.75 
mm using an aluminum compression element connected to 
a 10-N load cell, and measurements of the resultant force 
exerted by the lenses were collected. For experiments exam-
ining whether the effects on the biomechanics were reversible, 
a 5-N sensitive load cell was used and compressions were 
performed in disruptor- and vehicle-free TS. This was done 
immediately after the 15 min disruptor/vehicle treatment at 
the following time points: 1 min, 2 min, 4 min, 8 min, 16 min, 
32 min, 1 h, 2 h, 4 h, 8 h, 16 h, and 32 h after treatment. The 
force compression data for each lens were collected using 
Bluehill software (ver. 9, Instron).
Analysis of stiffness: Force data were adjusted to account 
for the buoyancy exerted by the surrounding solution on the 
compression element, as it displaced more or less test solution 
during compression and relaxation of the lens. The resulting 
Figure 1. Image of a lens in the compression chamber. The lens 
(arrow) is submerged in TS, sitting anterior side up on a pedestal 
and compressed from above by an aluminum compression element 
connected to a load cell.
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force-compression curves that were generated for each lens 
were then best fit to a three-parameter exponential curve with 
the equation y = y0 + ae
bx. As the b-coefficient of the expo-
nential equation is a unitless constant that describes the rela-
tionship of how rapidly the force increases as the compression 
distance increases, it was used to assess the relative stiffness 
between lenses [27,28] with larger numerical values for the 
b-coefficient representing steeper curves, and thus stiffer 
lenses. B-coefficients from each curve were extracted, and 
means and standard deviations were calculated from these 
data. Dimensionless b-coefficient values for whole lenses 
should not be confused with the Young’s Modulus, which 
is known to vary in different parts of the lens [29] and was 
not measured in this study. It should be noted there were no 
significant differences in the sizes of the control and treated 
lenses; thus, differences in the b-coefficients likely corre-
spond to differences in the Young’s Modulus of at least part 
of the lens, although our data cannot tell us which part.
Western blot: A western blot analysis was performed to 
confirm that disruptors had the expected effects on the lenses. 
Disruptor and vehicle treatments were identical to those for 
the compression trials. Lenses were dissected and separated 
into 1) BMC samples, which include posterior capsule and 
sheared ends of lens fiber cells still attached to the membrane, 
and 2) decapsulated lens fiber samples, composed of cortical 
and nuclear fibers. Each sample was separately ground using 
mini pestles and lysed with radioimmunoprecipitation assay 
buffer (RIPA; R0278, Sigma-Aldrich Co., Oakville, ON, 
Canada) containing a general use protease inhibitor cocktail 
(P2714, Sigma-Aldrich Co.). The total protein of the lens 
tissue samples was quantified using the BioRad DC protein 
assay (500–0111; BioRad Laboratories, Inc., Mississauga, 
ON, Canada). Samples were prepared with a Laemmli sample 
buffer, run on 10% precast gels (456–1033, BioRad Labora-
tories, Inc.) in the BioRad Mini-Protean System (165–8000, 
BioRad Laboratories, Inc.), transferred to a polyvinyldene 
f luoride (PVDF; 162–0175, BioRad Laboratories, Inc.) 
membrane, and visualized with antibodies specific to the 
protein being blotted. Mono- and polymeric actin levels in 
the lens capsule were quantified using a globular (g-) actin/
filamentous (f-) actin in vivo assay biochemistry kit (BKO37, 
Cytoskeleton, Inc., Denver, CO). In brief, lens samples were 
homogenized, and a detergent-based lysis buffer that stabi-
lizes and maintains the globular and filamentous forms of 
cellular actin was added. The lysate containing each sample 
was then centrifuged (21,100 × g, Thermo Scientific Sorvall 
Legend Micro) [21], with the resulting supernatant and pellet 
containing g-actin and f-actin, respectively. Actin levels 
in both the supernatant and pellet were then quantified by 
a western blot analysis for three replicates, each consisting 
of a minimum of four lens tissue extracts. ML-7 inhibits 
MLCK, which phosphorylates myosin; therefore, antibodies 
against phosphorylated myosin (M6068, Sigma-Aldrich) were 
used for ML-7-treated samples. An anti-beta actin antibody 
(ab8224, Abcam Inc., Toronto, ON, Canada) was used as 
a loading control. Secondary antibodies conjugated with 
horseradish peroxidase were detected by enhanced chemi-
luminescence using Amersham ECL prime (RPN2236, GE 
Healthcare, Mississauga, ON, Canada). Western blots were 
visualized using a Storm 860 scanner (GE Healthcare) and 
assessed using the ImageQuant software (GE Healthcare).
Optical quality: The optical quality of the lenses was assessed 
using a ScanTox© scanning laser monitor. In brief, lenses 
were placed anterior side down in a rectangular glass chamber 
in TS and 5% fetal bovine serum, with the latter used to 
visualize the helium-neon laser beams passing through the 
lens at various eccentricities from the optical axis. Refracted 
beams were captured and recorded with a camera, and back 
vertex focal lengths were calculated using software associ-
ated with the scanner. Beams passing through the sutures 
were omitted, as they produce highly inaccurate back vertex 
focal lengths. The optical quality of the lenses was assessed 
based on changes in scatter and spherical aberration (SA). 
For calculations of SA, data were first converted to dioptric 
values (vergences) using a thin lens approximation in water; 
the refractive index of water (nW = 1.33) was divided by the 
back vertex focal lengths (in meters). The vergences were 
then fitted using a third-order polynomial line of regression to 
determine the back vertex distance at the optical axis (Figure 
2). The amounts of SA were determined for a 1.5 mm pupil 
size by averaging the SA calculations for the positive (0 to 
0.75 mm) and negative (0 to −0.75 mm) eccentricities. As bird 
lenses typically show a high negative SA [22,30-32], scatter 
was quantified as the mean deviation of the various focal 
lengths from the best fitting third-order polynomial line of 
regression. Higher deviations indicated higher degrees of 
scatter.
Confocal microscopy: Blebbistatin- and latrunculin-treated 
lenses and the controls for these lenses were fixed with 2% 
(v/v) paraformaldehyde in TS. Lenses were permeabilized in 
toto using 0.05% v/v Triton X-100 in PBS before the addi-
tion of a mouse anti-myosin-light-chain antibody (M4401, 
Sigma-Aldrich, 1:100 dilution in PBS, 2 h at 37 °C) followed 
by a rabbit anti-mouse secondary antibody conjugated to 
Texas Red (1:500 in PBS, overnight at RT). Following a 
3×5 min wash, lenses were counterstained with phalloidin 
FITC (P5282, Sigma-Aldrich, 1:400 dilution in PBS, 15 min, 
RT). Lenses were mounted in toto posterior pole up onto 
slides using 5% (w/v) agar solution in water with 0.05 mg/
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ml phenylenediamene (P6001, Sigma-Aldrich; in 50% (v/v) 
glycerol in water). A coverslip coated with ProLong Gold 
(P36934, Life Technologies) was then placed on top of the 
posterior pole of the lens and adhered to the slide with the 
agar. The protein distribution of lenses was visualized using 
a Zeiss LSM 510 confocal microscope and images were 
captured and processed using the Zen 2011 software (Zeiss).
Nearest neighbor analysis: Protein distributions were quanti-
fied using a nearest neighbor analysis, which assesses the 
closeness of points of interest (POIs) on an image and assigns 
a value between 0 and 2.15, where a score of 0 represents 
clustered POIs, a score of 1 represents a random distribution 
of POIs, and a score of 2.15 is a highly regular distribution 
of POIs. For latrunculin-treated lenses (n = 3), the POIs used 
were the vertices of actin hexagons, while for blebbistatin-
treated lenses (n = 3), the POIs used were the center of myosin 
globules. POIs were targeted and selected using NIH Image 
or Scion Image software. Nearest neighbor values (Rn) were 
calculated using the equation
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Where DObs) is the mean observed nearest neighbor 
distance, a is the area, and n is the total number of POIs.
Statistical analysis: The effects of the disruptors on the 
stiffness and optical quality of the lenses were analyzed 
using a mixed-model analysis of variance (ANOVA), with 
disruptor versus vehicle as the repeated measure and the type 
of disruptor used as a factor. For the longitudinal (revers-
ibility) study, a two-way repeated-measured ANOVA was 
used with the disruptor versus vehicle as one measure and 
time as the other. Tukey or Bonferroni-corrected post-hoc 
multiple comparison tests were performed where applicable. 
Comparisons of the optical quality of the lenses, as well as 
of nearest neighbor values were assessed using paired t tests. 
For all statistical tests, results were considered significant at 
p≤0.05.
RESULTS
Force-compression curves were generated for each lens 
(Figure 3). A linear regression of the data to a three-param-
eter exponential curve (y = y + aebx) yielded mean r2 values 
(± SEM) of 0.9861±0.0217 (range: 0.8787 and 0.9999). For 
most pairs of lenses, treatment with disruptors was associated 
with a decrease in the stiffness of the lens, as indicated by 
the shallower force-compression curves (Figure 3, solid grey 
lines and filled symbols). Specifically, for 15 of 18 pairs of 
eyes in the latrunculin group, treated lenses exhibited rela-
tively lower stiffness values for the latrunculin-treated lenses 
compared to the vehicle-control, while three pairs showed 
the opposite trend, with stiffness in the latrunculin-treated 
lenses being relatively higher than in those exposed to the 
vehicle. The mean stiffness values reflected the general 
trend, with latrunculin-treated lenses being significantly 
lower (± SEM) at 2.64±1.28 compared to the vehicle-treated 
lenses at 4.15±1.15 (p = 0.0011; Figure 4A). Similarly, 14 of 
16 pairs of lenses showed relatively lower stiffness values 
for the blebbistatin-treated lenses compared to the vehicle-
treated counterparts, with two pairs showing the opposite 
trend. Again, the mean stiffness values (± SEM) were lower 
for the blebbistatin-treated lenses (3.25±0.23) than for those 
exposed to the vehicle (4.47±0.57; p = 0.0274; Figure 4B). 
Finally, for 12 of 14 pairs of lenses, the stiffness values of the 
ML-7 treated lenses were relatively lower compared to the 
vehicle-treated lenses, while the values for two pairs of lenses 
were relatively higher. The mean stiffness value for the ML-7-
treated lenses was, again, lower than for the counterpart eyes 
(2.90±1.19 versus 4.49±1.23, respectively; p = 0.0027; Figure 
4C). A mixed model analysis revealed neither significant 
differences in the stiffness levels between the disruptors (p = 
0.2379) nor an interaction effect (p = 0.7483).
Figure 2. Effects of disruptors 
on lenticular optics. Line graph 
showing the focal length (mm) 
at various eccentricities (mm) of 
a typical avian crystalline lens. 
Graphs were fitted with third-order 
polynomial equations to calculate 
the amount of scatter and SA.
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A western blot analysis indicated that latrunculin and 
ML-7 treatments were effective in disrupting actin levels 
and myosin phosphorylation, respectively, at both the BMC 
and the lens fibers. Actin levels in latrunculin-treated lenses 
were quantified using a g-actin/f-actin in vivo assay kit, 
which revealed a large decrease in f-actin both at the BMC 
and in the lens fiber cells as a result of lens tissue treatment. 
In BMC samples treated with latrunculin, the mean intensity 
(± SEM) of f-actin was 12.0±1.2, while the mean intensity of 
g-actin was 19.3±1.9, representing 38.4±0.5% and 61.6±0.5% 
of the total actin amount, respectively, indicating substantial 
depolymerization of f-actin as a result of latrunculin treat-
ment (Figure 5A, top panel). In comparison, control samples 
showed a ratio of approximately 1:1, with mean intensities of 
f- and g-actin at 14.2±1.4 and 13.7±1.4, representing 51.0±0.5% 
and 49.0±0.5% of the total actin amount, respectively. In the 
lens fiber samples treated with latrunculin, the mean intensity 
(± SEM) of f-actin was 10.0±1.6, while the mean intensity of 
g-actin was 18.3±1.9, representing 35.4±0.6% and 64.7±0.7% 
of the total actin amount, respectively (Figure 5A; bottom 
panel). In comparison, control samples again showed a ratio 
of approximately 1:1, with mean intensities of f- and g-actin at 
13.4±1.3 and 13.3±1.2, representing 50.1±0.5% and 49.9±0.5% 
of the total actin amount, respectively. The relative intensi-
ties of phospho-myosin were lower in both BMC (by 49.8%; 
treated versus control: 18.6±3.0 versus 55.5±1.9, respectively) 
and lens fiber cell samples (by 35.7%; treated versus control: 
9.1±2.2 versus 19.2±3.1, respectively) when treated with ML-7 
(Figures 5B, left and right panels, respectively), indicating an 
ML-7-dependent inhibition of myosin phosphorylation.
Confocal images indicated that latrunculin led to the 
rearrangement and thinning of the actin cables at the basal 
membrane (Figure 6). Actin in the latrunculin-treated lenses 
appeared different from the vehicle-treated lenses, which 
showed the typical punctate staining of the highly regular 
hexagonal vertices. Additionally, myosin bundles localized 
at the center of the actin formations appeared more variable 
in size and neighboring distance. A nearest neighbor analysis 
indicated a significant increase in the disorder of the myosin 
associated with the actin lattice (Rnm for treated lenses: 
Figure 3. Force-compression curves 
of all lenses. Mean force ± SEM of 
(A) latrunculin-, (B) blebbistatin-, 
and (C) ML-7-treated lenses (filled 
symbols) and their controls (empty 
symbols), as a function of compres-
sion. Force-compression curves of 
individual disruptor-treated (solid 
gray lines) and vehicle-treated 
(dashed gray lines) lenses are also 
included.
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Figure 4. Effects of disruptors on 
lenticular stiffness. Mean stiffness 
values ± SEM of disruptor- and 
vehicle-treated lenses for (A) 10 
µM latrunculin (n = 18), (B) 10 µM 
blebbistatin (n = 16), and (C) 10 µM 
ML-7 (n = 14). Asterisks denote 
significant differences (all groups 
p≤0.0274).
Figure 5. Effects of disruptors on 
protein concentrations in the lens. 
(A) Western blots of f- and g-actin 
in BMC and lens fiber cell samples 
treated with latrunculin. Numbers 
in parentheses represent the mean 
percentage optical density (±SEM) 
relative to the total amount of actin. 
(B) Western blots of phospho-
myosin in BMC and lens fiber 
cell samples treated with ML-7. 
Numbers in parentheses represent 
the mean optical densities (±SEM). 
β-actin was used as the loading 
control.
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1.751±0.023 versus Rnm for control lenses: 2.056±0.054; p = 
0.0025). The actin distribution in latrunculin-treated lenses 
had an Rna (± SEM) of 1.826±0.047, while its vehicle-treated 
counterpart had an Rna of 2.091±0.054, indicating a small 
increase in f-actin disorder (Figures 6A, B), although these 
changes were not significant (p = 0.0593).
Both actin and myosin organizations were adversely 
affected by blebbistatin. The myosin distributions in lenses 
treated with blebbistatin were even less ordered than those 
observed in latrunculin-treated lenses, and treated lenses 
showed an even lower Rnm of 1.576±0.081, while their vehicle-
treated counterparts had an Rnm of 2.054±0.031 (p = 0.0183, 
Figures 6C, D). The actin distribution was also affected; 
blebbistatin-treated lenses lost the regular repeating arrays of 
punctate staining, and the Rna of 1.158±0.022 in these lenses 
was significantly different from that in the control lenses, at 
an Rna of 2.001±0.005 (p = 0.0183), indicating a large increase 
in disorder.
Despite the rearrangement of the cytoskeletal proteins 
at the BMC, the optical quality of disruptor-treated lenses, 
assessed using two criteria, scatter and SA (Table 1), were 
unaffected. The disruptor-treated lenses showed neither a 
difference in the amounts of scatter compared to their respec-
tive controls (p≥0.4696; Table 1) nor did any disruptor treat-
ments result in differences in the amount of SA (p≥0.2245; 
Table 1). In the longitudinal (reversibility) compression trials, 
it was found that lenses treated with latrunculin took the 
longest to recover, showing significant differences in stiff-
ness up until the 4-h mark, (mean stiffness ± SEM at 4 h: 
control lenses, 6.17±0.43 versus treated lenses, 4.98±0.56; p 
= 0.0730; Figure 7A). Lenses treated with blebbistatin were 
found to have a recovery time of 1 h (mean stiffness at 1 
h: control lenses, 5.37±0.19 versus treated lenses, 5.27±0.51; 
p = 1.000; Figure 7B). Lenses treated with ML-7 had the 
quickest recovery time at 8 min (mean stiffness at 8 min: 
control lenses, 6.02±0.36 versus treated lenses, 5.17±0.40; p 
= 1.000; Figure 7C).
Figure 6. Effects of disruptors on 
actin and myosin distributions 
in the lens. Confocal images of 
posterior lens capsules showing 
the distribution of actin (green) and 
myosin (red) in a (A) latrunculin-
treated lens and (B) its vehicle-
treated counterpart, as well as a (C) 
blebbistatin-treated lens and (D) its vehicle-treated counterpart. Scale bar = 5 µm for all images. Rn values for actin (Rna, green) and myosin 
(Rnm, red) distributions are included.
Table 1. Mean spherical aberraTion (D) ± seM anD Mean scaTTer (MM) ± seM for laTrun-
culin-, blebbisTaTin-, anD Ml-7-TreaTeD lenses anD Their conTrols. 
Disruptor
Spherical aberration (D) Scatter (Mean deviation; mm)
Treated Control P value Treated Control P value
Latrunculin
−11.80±0.50 
(−9.13 to −13.94)
−11.57±0.48 
(−9.51 to −14.30)
0.6093
1.15±0.03 
(1.00 to 1.36)
1.15±0.04 
(0.93 to 1.36)
0.9858
Blebbistatin
−11.62±0.31 
(−9.84 to −13.13)
−11.59±0.26 
(−10.13 to −12.95)
0.9212
1.19±0.07 
(1.01 to 1.83)
1.14±0.02 
(1.06 to 1.21)
0.4696
ML-7
−11.94±0.69 
(−7.95 to −15.06)
−12.44±0.78 
(−7.54 to −16.84)
0.2245
1.15±0.03 
(0.91 to 1.25)
1.13±0.05 
(0.81 to 1.32)
0.7526
Ranges are in parentheses.
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DISCUSSION
The compression trials showed that treatment with actomyosin 
disruptors results in significant changes in the distributions 
of actin and myosin and significant decreases in the stiffness 
of the whole lens. While it is possible that other mechanisms 
were responsible for lens softening, the simplest explanation 
is that the decrease in stiffness was a direct result of the 
changes to the structure of the actomyosin lattice wrought by 
the disruptors. It should be noted that a small number of lenses 
treated with inhibitors in the compression trials showed an 
increase in stiffness; however, this result is likely due to the 
biologic variation among lenses. It is known that variations 
exist in lenses; lenses of the same age will show variations in 
thickness and the anterior surface shows a higher variation in 
curvature than the posterior surface. Compression forces are 
presumably related to the thickness and the shape of the lens; 
therefore, variations in both these parameters could confer 
variations in the compression response [33].
Responses were reversible for all three disruptors, but 
the kinetics of recovery differed. Latrunculin-treated lenses 
recovered the slowest, perhaps due to the ubiquitous presence 
of actin microfilaments, found not only at the lens capsule 
and BMC, but also within the lens cortex and nucleus, the 
latter two of which form the bulk of the lens [7]. More actin 
would presumably require more time to reassemble. Although 
optimal assembly conditions for actin and myosin differ, it 
should be noted that, at least theoretically, actin has a slower 
association rate than myosin II. The elongation rates of actin 
filaments are 11.6±1.2×10−6 M−1s−1 at the barbed ends and 
1.3±0.2×10−6 M−1s−1 at the pointed ends [34] compared to 
myosin II, which has an immensely faster rate of ≥2.0×108 
M−1s−1 [35]. It is most likely that blebbistatin and ML-7-treated 
lenses were much faster in their recovery times because these 
disruptors do not physically segregate the target protein into 
its monomeric components. Instead, the myosin disruptors 
act by preventing phosphorylation and competitively binding 
to key structures in the actomyosin cascade, a process that is 
presumably easier and quicker to reverse [25,36].
Figure 7. Time course of lenticular 
st iffness following disruptor 
removal. Longitudinal recovery 
effects of (A) 10 µM latrunculin (n 
= 6), (B) 10 µM blebbistatin (n = 
6), and (C) 10 µM ML-7 (n = 6) on 
lens stiffness compared to vehicle 
controls. Asterisks (*) indicate 
significant differences between 
disruptor- and vehicle-treated 
lenses.
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It should be noted that in preliminary trials, the acute 
treatment of lenses with a higher concentration of ML-7 
(100 µM) resulted in lens stiffening, with 4 of 16 lenses 
physically bursting during force-compression trials (data not 
shown). Stiffening as a result of high concentrations of ML-7 
could be due to a biphasic dose response of the MLCK inhib-
itor. Indeed, in the case of cell spreading, another process 
mediated by the dynamics of the actomyosin network, ML-7 
has opposite effects in COS7 carcinoma cells when its dose 
is increased by a factor of five [37]. Moreover, results of 
two-dimensional gel electrophoresis of 100 µM ML-7-treated 
posterior lens capsule tissues suggest increases in protein 
phosphorylation compared to samples treated with10 µM 
ML-7 (data not shown).
In a related study on lens shape changes by Luck and 
Choh [21], low and high concentrations of ML-7 resulted 
in longer and shorter avian lens focal lengths, respectively. 
Although the directionality of 10 and 100 µM changes is in 
agreement with the stiffening observed in our experiment, 
we did not observe any focal length changes with these two 
ML-7 concentrations. One difference may be that Luck and 
Choh conducted the optical trials on lenses in situ, where 
the lens was still in its accommodative apparatus, while we 
conducted our optical trials on lenses in vitro, i.e., on lenses 
that had been extracted from their surrounding tissue. In our 
experiments, lenses may have been “rounded up,” a phenom-
enon that has been described before for lenses separated 
from their surrounding anatomy [38]. This idea seems to be 
supported by the average focal length of our vehicle-treated 
lenses (14.1±0.2 mm; data not shown), which was shorter and 
therefore more powerful than the vehicle-treated lenses in 
Luck and Choh’s study (19.6 mm). It is possible that in our 
experiment, lenses were maximally rounded and therefore, 
any further release of tension associated with the actin-
myosin network would be too small to detect.
Indications that cytoskeletal proteins might play a role 
in lenticular biomechanics were noted by Rafferty et al. [39], 
who showed that increasing intracellular calcium levels in 
rabbit anterior epithelial cells in the lens resulted in changes 
in actin stress fiber distributions. Although the concentra-
tion of myosin is generally lower than actin in contractile 
networks, such as those found in lens epithelial cells [14], 
it is nonetheless crucial for structural integrity. Two of the 
disruptors used targeted myosin or myosin function and both 
were able to exert effects that were similar to those exerted 
by the actin disruptor. However, it should also be noted that 
cytoskeletal integrity is not limited to the actomyosin system; 
intermediate filaments and microtubules also play a role in 
maintaining the cellular architecture [8]. Lenses from mice 
in which a gene for beaded filaments, which belongs to the 
intermediate filament gene family, is knocked out are less 
stiff than those from wild-type mice are [17]. Our results add 
to the growing body of evidence showing the importance 
of cytoskeletal protein integrity to lenticular biomechanics. 
While studies by Fudge et al. [17] and the present study 
examined how disrupting cytoskeletal integrity affects the 
biomechanics of the lens as a whole, a previous study inves-
tigated their effects on lenticular cells individually. Unlike 
our results, Hozic et al. [40] showed no difference in the 
stiffness of the individual lenticular cells with cytochalasin, 
an actin disruptor. The difference between the present study 
and that of Hozic et al. [40] may be related to the disruptor 
used (latrunculin versus cytochalasin B); cytochalasin works 
by inhibiting actin polymerization, essentially preventing 
the formation of actin networks (blocks monomer addition), 
while latrunculin depolymerizes f-actin.
In both the acute and longitudinal compression trials, 
lenses were kept in TS in temperatures at or above 5 °C to 
retard cell metabolism and prevent the tissue from degrading, 
particularly for the longitudinal trials that required ex vivo 
viability for durations greater than 32 h. It should be noted 
that lenses in situ would be closer to body temperature [41]; 
moreover, cold temperatures could promote the depolymer-
ization of actin microfilaments. Hall et al. [42,43] showed 
that cells exposed to a temperature of 4 °C for 2–4 h exhibit 
a marked thinning of actin filaments. However, Matthews 
et al. [44] found no effects of these conditions on the actin 
structure. Our lenses were exposed to a minimum of 5 °C for 
a maximum of 15 min, and thus the cold-induced depolymer-
ization of f-actin should have been minimal. Furthermore, 
any cold-induced depolymerization was accounted for by our 
control lenses, which experienced identical conditions aside 
from the disruptor treatment.
The confocal imaging and western blots together indicate 
that the disruptors penetrated the lens at a deep enough level 
to affect the cytoskeletal distribution at the BMC in addi-
tion to the lens fiber cells. Given that confocal images were 
acquired between 12 and 13 µm below the lens capsule, it 
is known that the depth of the disruptor penetration is at 
least to this extent. It is unclear how deeply the disruptors 
penetrate the lens, as well as whether they diffuse uniformly 
throughout the lens; however, it is sure to be different, as a 
disparity between the diffusion patterns at the surface of the 
lens compared to the lens core syncytium exists and has been 
shown by Shestapolov and Bassnett [45,46].
While f-actin depolymerization was an expected 
outcome of latrunculin treatment, myosin organization was 
also affected (Figure 6A). It has been proposed that in order 
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for myosin II to remain in the cytoskeleton, it must be bound 
to stable actin [47]. Similarly, blebbistatin also appears to 
enhance the depolymerization of f-actin (Figure 6C). Bleb-
bistatin is known to disassemble actin [48], presumably by 
reducing myosin activity and therefore actin cross-linkings. 
Although ML-7 affects phosphorylation and therefore 
the ability of actin and myosin to interact, it would not be 
expected to physically alter the architecture of the actomyosin 
network, which was indeed the case (ML-7-treated Rn = 
2.02±0.02 versus vehicle-treated Rn = 2.01±0.02; data not 
shown).
Our results showed that despite the cytoskeletal distri-
bution changes at the BMC and the measured changes in 
stiffness, the optics of the isolated lenses were unaffected 
by the disruptors (Table 1), and during the acute study trials, 
it was noted that lenses maintained transparency (note the 
clarity of the lens in Figure 1). Either the disruption at the 
BMC was too small to confer a change in SA and scatter, or 
the regular arrangement and tight packing of the lens fiber 
cells rendered any disruption of the actomyosin distributions 
negligible. However, while lenses were clear during the acute 
experiment, the long-term effects of disruptors on lenticular 
transparency remain unknown; a qualitative assessment of 
the lenses indicated that incubation with disruptors for about 
1 h resulted in turbidity and the development of cataracts 
(data not shown). Whether turbid lenses can recover optical 
clarity also remains unknown; therefore, the use of cyto-
skeletal disruptors as permanent effectors for changing lens 
biomechanics must take into account other possible effects on 
functions such as optical clarity.
Other questions that need to be answered include 
whether these disruptors can be as effective on older lenses. 
As mentioned above, the focus of this experiment was to 
determine whether disruption of the actomyosin lattice could 
alter lenticular biomechanics, and for experimental conve-
nience, we used young chicks. While it is tempting to relate 
our results to presbyopia, which is accompanied by profound 
increases in lenticular stiffness with age [49-51], further 
investigations will require the use of older experimental 
animals.
We have found that by targeting the cytoskeletal proteins 
that are known to have structural roles in cells, lenses become 
less stiff, but whether the lens plays more than a passive role 
during accommodation remains unclear. The physiology and 
cellular arrangement of the lens are mostly dedicated to main-
taining optical clarity by ordering the fiber cells into a regular 
arrangement and reducing the intercellular spaces between 
them so light is less scattered. The hexagonal shape conferred 
upon the lens fiber cells fulfils both functions and therefore, 
the finding that a geodesic hexagonal network is present at the 
posterior surface may simply reflect the shape of the highly 
organized fiber cells and function to resist deformations that 
could disrupt this organization.
In summary, we found that the disruption of actomyosin 
networks in young avian lenses causes significant decreases 
in the stiffness of isolated lenses, but there are no differences 
in their optical properties. These results are consistent with 
the hypothesis that lens stiffness may be actively tuned via 
adjustments to the actomyosin networks in lens cells. The 
lack of an effect on lens optical properties may have been 
due to a “rounding up” artifact caused by the isolation of the 
lens from the eye.
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